Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

Abroad (travel likely)RecruitingPHASE1

Conditions

Lupus Nephritis (LN)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Mayo Clinic, Rochester, Minnesota, United States

  • Baylor College of Medicine, Houston, Texas, United States

  • Centre Hospitalier Universitaire (CHU) Bordeaux, Bordeaux, New Aquitaine, France

  • University Hospital Regensburg, Regensburg, Bavaria, Germany

  • University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany

  • Hallym University Sacred Heart Hospital, Anyang-si, Gyeonggi-do, South Korea

  • Seoul National University Hospital, Seoul, South Korea

  • Samsung Medical Center, Seoul, South Korea

  • Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea

  • Hospital Universitario Virgen del Rocio, Seville, Andalusia, Spain

  • Clinica Universidad de Navarra, Pamplona, Navarre, Spain

  • Hospital Gregorio Maranon, Madrid, Spain

  • Hospital Universitario 12 de Octubre, Madrid, Spain

  • Hospital Regional Universitario de Malaga, Málaga, Spain

  • Changhua Christian Hospital, Changhua, Taiwan

  • Taichung General Veterans Hospital, Taichung, Taiwan

  • National Taiwan University Hospital, Taipei, Taiwan

  • Taipei Veterans General Hospital, Taipei, Taiwan

Study leads
  • Clinical Trial Management

    Study Director

    Regeneron Pharmaceuticals